This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ0505O_L.jpg
Glofitamab is intended for patients with relapsed or refractory large b-cell lymphoma.
The FDA is expected to make a decision on approval of the cancer immunotherapy by July 1, 2023.
